COPD

Inhaled anticholinergic bronchodilator tiotropium as an add-on therapy has the potential to reduce exacerbations.

The first once-daily, triple-therapy inhaler drug was originally approved by the FDA in September.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Researchers studied recently-referred COPD patients and what attributes put them at risk for poor inhaler device technique.

Clinicians now have pharmacologic and nonpharmacologic treatments that can be very effective for the common condition.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.

Less than 40% of patients in a recent study could perform a perfect inhalation with their device. That's a problem for COPD and asthma patients.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

Alpha-1 Antitrypsin Deficiency is often diagnosed long after it's developed, and late diagnosis leads to worse outcomes.

Stay updated on the biggest headlines with MDNN from October 20, 2017.

As COPD exacerbations continue to plague patients, the AIRWISE trial will examine LAMA/LABA/ICS combinations.

“We are constantly looking for new molecules with which to treat COPD patients.”

The combination is the first once-daily therapy approved in the US that combines 3 active molecules in a single inhaler.

Produced by GlaxoSmithKline, 100 mg mepolizumab used in conjunction with maximal guideline-recommended therapy, showed a consistent 18% to 20% reduction.

The single-dose inhaler was the first of its kind to get positive recommendation from EMA's Committee for Medicinal Products for Human Use.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

COPD-related deaths increased 11.6% since 1990, and cases increased 44.2% to 174.5 million.